I don't think it's that management can't give a guidance, i think it is that they don't want to, lest they be held to it in a challenging climate. Management has given a couple guiding statements in favour of this theory of mine, specifically clarifying their belief the generics business has stablised and they expect higher margins and possibly increased sales due to new products (FY20), confirmation MCS is still growing strongly, mentioning that Greenville (MCS manufacturing) has grown from 1 to 4 customers with a number of products in 'late stage development' or 'pending approval' and specifically singling out the women's health product portfolio and margins therein.
I don't like it but it is not an uncommon strategy.
Personally I get the tone of cautious optimism from MYX management.
MYX Price at posting:
44.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)